by
Gus Iversen, Editor in Chief | December 17, 2025
Royal Philips has entered an agreement to acquire SpectraWAVE Inc., a Massachusetts-based developer of AI-enabled intravascular imaging and physiology tools for coronary interventions.
The deal is expected to strengthen Philips' portfolio in image-guided therapy, particularly in the coronary segment, by integrating SpectraWAVE’s HyperVue imaging system and X1-FFR technology into its existing platforms. HyperVue combines next-generation optical coherence tomography (DeepOCT) with near-infrared spectroscopy to deliver detailed, automated imaging inside the coronary arteries. X1-FFR, meanwhile, offers noninvasive fractional flow reserve calculations derived from standard angiograms.
Philips said the integration of these tools into its Azurion platform will broaden clinician access to advanced imaging and diagnostic capabilities, enabling more personalized and efficient procedures. Azurion is currently used in over 80 countries and supports more than 7.6 million procedures annually.
Ad Statistics
Times Displayed: 344592
Times Visited: 21056 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
“With the addition of SpectraWAVE’s AI-powered innovations in high-definition intravascular imaging and angio-based physiological assessment, we are doubling down on image-guided therapy and expanding our portfolio in the coronary intervention segment,” said Roy Jakobs, CEO of Royal Philips.
Founded in 2017, SpectraWAVE employs more than 70 people and specializes in Enhanced Vascular Imaging and AI-driven diagnostic software. Its X1-FFR solution is designed to simplify workflow by delivering real-time ischemia assessments using only X-ray imaging, without requiring a pressure wire.
“Philips shares our deep conviction that the convergence of intravascular imaging, coronary physiology and AI can fundamentally improve how every patient with coronary disease is treated,” said Eman Namati, CEO of SpectraWAVE.
Philips currently offers intravascular imaging and physiology tools such as the Eagle Eye Platinum digital IVUS and OmniWire iFR technology. The company expects the acquisition to enhance its capacity to support clinicians in guiding, treating, and confirming coronary interventions in a single setting.
Financial details of the transaction were not disclosed.
